{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:18:06Z","timestamp":1795097886988,"version":"4.10.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2025.10.029","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:29:15Z","timestamp":1762302555000},"page":"1381-1387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Ang","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengju","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.10.029_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000462","article-title":"Targeted therapy in cervical cancer","volume":"3","author":"Vora","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.31664","article-title":"Global cancer incidence in older adults, 2012 and 2035: A population-based study","volume":"144","author":"Pilleron","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0004","doi-asserted-by":"crossref","first-page":"969","DOI":"10.6004\/jnccn.2019.7289","article-title":"Benefit of cisplatin with definitive radiotherapy in older women with cervical cancer","volume":"17","author":"Xiang","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000338555","article-title":"Heavy cervical cancer burden in elderly women: How can we improve the situation?","volume":"56","author":"Skaznik-Wikiel","year":"2012","journal-title":"Acta Cytol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0006","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ijrobp.2021.03.003","article-title":"The dynamic alternation of local and systemic tumor immune microenvironment during concurrent chemoradiotherapy of cervical cancer: A prospective clinical trial","volume":"110","author":"Li","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0007","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12885-017-3503-2","article-title":"Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-018-0705-y","article-title":"Toxicity of cancer therapies in older patients","volume":"20","author":"Le Saux","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0009","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the egfr in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0011","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdq723","article-title":"Epidermal growth factor receptor as a biomarker for cervical cancer","volume":"22","author":"Soonthornthum","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0012","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/modpathol.2010.239","article-title":"Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer","volume":"24","author":"Schrevel","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0013","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4161\/mabs.28915","article-title":"Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor","volume":"6","author":"Tundidor","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0014","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fphar.2017.00595","article-title":"Upregulation of hla class i expression on tumor cells by the anti-egfr antibody nimotuzumab","volume":"8","author":"Garrido","year":"2017","journal-title":"Front Pharmacol"},{"issue":"suppl 16","key":"10.1016\/j.ijrobp.2025.10.029_bib0015","article-title":"Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 cc3 study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"Recist 1.1\u2014update and clarification: From the recist committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas [Using the common terminology criteria for adverse events (ctcae\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies]","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"suppl 15","key":"10.1016\/j.ijrobp.2025.10.029_bib0018","article-title":"Safety and efficacy of nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy for locally advanced cervical squamous cell cancer","volume":"37","author":"Qu","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0019","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/cncr.30667","article-title":"Cervical cancer: A global health crisis","volume":"123","author":"Small","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2011.07.012","article-title":"Clinical outcome of protocol based image (mri) guided adaptive brachytherapy combined with 3d conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"Potter","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (engot-cx11\/gog-3047\/keynote-a18): A randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0022","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/IGC.0000000000001029","article-title":"Definitive chemoradiotherapy in elderly cervical cancer patients: A multiinstitutional analysis","volume":"27","author":"Guler","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40944-020-00476-7","article-title":"Treatment compliance and clinical outcomes in older patients with cervical cancer treated with radio(chemo)therapy\u2014a retrospective analysis","volume":"19","author":"Khondekar","year":"2021","journal-title":"Indian J Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0024","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jgo.2018.10.005","article-title":"Impact of age on receipt of curative treatment for cervical cancer: An analysis of patterns of care and survival in a large, national cohort","volume":"10","author":"Albert","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/ijgc-2018-000077","article-title":"Radiation therapy for elderly patients with uterine cervical cancer: Feasibility of curative treatment","volume":"29","author":"Hata","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0026","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/jcm9061653","article-title":"Interaction between the number of chemotherapy cycles and brachytherapy dose\/volume parameters in locally advanced cervical cancer patients","volume":"9","author":"Escande","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.maturitas.2014.04.018","article-title":"Cervical cancer in the older woman","volume":"78","author":"Elit","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0028","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejogrb.2018.06.032","article-title":"A study of treatments and outcomes in elderly women with cervical cancer","volume":"228","author":"Shimamoto","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0029","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3389\/fonc.2020.01327","article-title":"Nimotuzumab combined with irradiation enhances the inhibition to the hpv16 e6-promoted growth of cervical squamous cell carcinoma","volume":"10","author":"Xu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.994726","article-title":"Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials","volume":"12","author":"Yuan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0031","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1002\/mco2.608","article-title":"Epidermal growth factor receptor\u2011targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: A propensity score matching real-world study","volume":"5","author":"Zhang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0032","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for k-ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2021.06.032","article-title":"Concurrent chemoradiation therapy with or without nimotuzumab in locally advanced squamous cell lung cancer: A phase 2 randomized trial","volume":"111","author":"Qiu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0034","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41416-023-02388-7","article-title":"Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (escc): Interim analysis from a phase 3 clinical trial","volume":"129","author":"Meng","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.4161\/cbt.6.9.4539","article-title":"Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody nimotuzumab","volume":"6","author":"Arteaga","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0037","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","article-title":"Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile","volume":"11","author":"Garrido","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0038","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21147\/j.issn.1000-9604.2021.01.06","article-title":"Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase ii clinical trial","volume":"33","author":"Yang","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0039","first-page":"2013","article-title":"Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer","volume":"24","author":"Cao","year":"2019","journal-title":"J BUON"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0040","article-title":"Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.10.029_bib0041","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/15384047.2015.1026483","article-title":"A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer","volume":"16","author":"Cetina","year":"2015","journal-title":"Cancer Biol Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506420X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506420X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:28:18Z","timestamp":1795094898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162506420X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S036030162506420X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.10.029","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}